OR WAIT 15 SECS
A recent roundtable moderated by Rob Jekielek of The Harris Poll gathered five biopharma CEOs to discuss the industry’s shifting reputational landscape in the public eye.
Anne E. White, president, Lilly Oncology, talks about how the lessons she learned from leading a startup helped her to speed Lilly’s drug development from target identification through successful launch.
Liz Barrett, CEO, UroGen Pharma: A Speciality Calling in Cancer
Click here to read the articles and download the PDF
Highlighted Videos
October 20, 2020
Lise Stevens explores what difference the ISO IDMP (Identification of Medicinal Products) data standards would have made in a COVID-19 context — in applications ranging from pharmacovigilance adverse event reporting and electronic prescribing to falsified medicines control.
The Medical Affairs Digital Strategy Council's Mary Alice Dwyer and Indegene's Sameer Lal talk to Pharm Exec about how digital solutions can help the Medical Affairs function take a leadership role in ensuring fast, efficient, and meaningful responses to all stakeholders at a time of intense pressure.
October 18, 2020
This week's much-anticipated meeting of FDA’s vaccine advisory committee will address critical issues related to the testing and approval of vaccines to prevent COVID-19 infection.
October 15, 2020
Sanjeev Luther, president and CEO of Rafael Pharmaceuticals, discusses how he managed to turn around a company on the brink of bankruptcy and advance clinical trials for its lead cancer drug through COVID-19.
Gabi Hanna, MD highlights the need for an effective therapy for acute pancreatitis.
Following the announcement of his new role, Pharm Exec had the chance to speak with Daniel Schroen, PhD about his past experience as well as the landscape of the therapeutic development industry.
Therapeutic companies that work with rare diseases must take early steps to build relationships with patients, caregivers, and HCPs.
October 14, 2020
When the people are the sole assets.
